PreveCeutical Medical (PRVCF) Ratios
PreveCeutical Medical Ratios
PRVCF's free cash flow for Q2 2026 was $-273.46K. For the 2026 fiscal year, PRVCF's free cash flow was increased by $0.00 and operating cash flow was $-273.46K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.15 | 0.02 | 0.01 | 0.01 | 0.03 |
| Quick Ratio | 0.15 | 0.02 | 0.01 | 0.01 | 0.03 |
| Cash Ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| Solvency Ratio | -0.20 | 0.00 | -0.21 | -0.31 | -0.40 |
| Operating Cash Flow Ratio | -0.24 | -0.06 | -0.05 | -0.05 | -0.16 |
| Short-Term Operating Cash Flow Coverage | -0.37 | -0.10 | -0.08 | -0.07 | -0.34 |
| Net Current Asset Value | $ -6.62M | $ -6.75M | $ -5.90M | $ -4.76M | $ -4.18M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 3.23 | 19.77 | 21.12 | 17.09 | 18.17 |
| Debt-to-Equity Ratio | -0.75 | -0.67 | -0.66 | -0.70 | -0.71 |
| Debt-to-Capital Ratio | -2.98 | -2.05 | -1.97 | -2.30 | -2.49 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.01 | 0.00 | 0.00 | -0.69 |
| Financial Leverage Ratio | -0.23 | -0.03 | -0.03 | -0.04 | -0.04 |
| Debt Service Coverage Ratio | -0.27 | -0.18 | -0.23 | -0.36 | -0.47 |
| Interest Coverage Ratio | -10.44 | -2.48 | -3.11 | -4.63 | -1.92 |
| Debt to Market Cap | 0.33 | 0.33 | 0.29 | 0.25 | 0.23 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Debt to EBITDA | -3.45 | -5.26 | -4.01 | -2.61 | -3.51 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 93.70% | 0.10% | 100.00% | 100.00% | 98.83% |
| EBT Per EBIT | 50.21% | 144.58% | 132.33% | 134.96% | 194.58% |
| Return on Assets (ROA) | -109.38% | -0.52% | -702.15% | -783.23% | -1071.07% |
| Return on Equity (ROE) | 25.37% | 0.02% | 22.06% | 31.96% | 42.07% |
| Return on Capital Employed (ROCE) | 59.39% | 12.36% | 16.67% | 23.68% | 36.98% |
| Return on Invested Capital (ROIC) | 339.03% | 37.33% | 51.12% | 78.20% | 75.53% |
| Return on Tangible Assets | -122.47% | -0.98% | -1968.78% | -2293.36% | -2033.60% |
| Earnings Yield | -11.14% | -0.01% | -9.52% | -11.36% | -13.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.01 | 0.02 | 0.03 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -16171.33 | -32913.76 | -21428.75 | -13698.81 | -27429.34 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 16171.33 | 32913.76 | 21428.75 | 13698.81 | 27429.34 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -581.63 | -237.18 | -74243.50 | 0.00 | -7.72 |
| Capital Expenditure Coverage Ratio | -581.63 | -237.18 | -74243.50 | 0.00 | -7.72 |
| Operating Cash Flow Coverage Ratio | -0.37 | -0.10 | -0.08 | -0.07 | -0.15 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -12.11% | -3.19% | -2.22% | -1.71% | -3.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.93 | -11.36 | -10.50 | -8.81 | -7.35 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -2.28 | -2.02 | -2.32 | -2.81 | -3.09 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.26 | -31.30 | -45.06 | -58.59 | -26.37 |
| Price-to-Operating Cash Flow Ratio | -8.27 | -31.43 | -45.06 | -58.59 | -29.78 |
| Price-to-Earnings Growth (PEG) Ratio | -0.33 | 1.36 | 0.74 | 0.50 | 0.12 |
| Enterprise Value Multiple | -13.95 | -21.27 | -18.02 | -13.18 | -18.81 |
| Enterprise Value | 18.89M | 17.81M | 17.22M | 16.27M | 15.61M |
| EV to EBITDA | -13.95 | -21.27 | -18.02 | -13.18 | -18.81 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -10.96 | -41.57 | -57.97 | -73.08 | -32.42 |
| EV to Operating Cash Flow | -10.98 | -41.75 | -57.97 | -73.08 | -36.61 |
| Tangible Book Value Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Shareholders’ Equity Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 0.94 | 0.00 | 1.00 | 1.00 | 0.99 |
| Interest Burden | 1.24 | 1.39 | 1.32 | 1.19 | 2.09 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.09 | 0.36 | 0.23 | 0.15 | 0.25 |
Currency in CAD
